Correlation Between Metabolic Syndrome and Serum Ghrelin Levels in Bipolar Patients
Yükleniyor...
Dosyalar
Tarih
2010
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
AVES
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu araştırmada ikiuçlu bozukluk hastalarında serum ghrelin düzeyleri ve Metabolik Sendrom (MetS) arasında bir ilişkinin olup olmadığının incelenmesi amaçlanmıştır.
Yöntemler: Altmış ikiuçlu bozukluk hastası ve 30 sağlıklı gönüllü çalışmaya da-
hil edildi. Hasta grubu atipik antipsikotik (risperidon, ketiapin, olanzapin) ve duy- gudurum düzenleyici (lityum, valproik asit, karbamazepin, lamotrijin) kullanımı- na göre iki ayrı gruba ayrıldı. Serum ghrelin seviyeleri insan ghrelin ELISA kitle- ri aracılığıyla ölçüldü. Hasta grubunda, NCEP ATP III (Adult Treatment Protocol of the National Cholesterol Education Programme) ölçütlerine göre MetS tanısı aşağıdakilerden 3 ya da daha fazlasının karşılanması ile değerlendirilmiştir.
Bulgular: Çalışmaya alınan bipolar hastaların %51.7'si (n=31) sadece atipik an-
tipsikotik (AA) tedavisi alırken, %48.8'ü (=29) sadece duygudurum düzenleyeci- si (DD) kullanıyordu. Hasta grubunda %36.7 (n=22) hastaya MetS tanısı konul- muştur. Hasta grubunda MetS olan ve olmayanlar arasında ghrelin düzeyleri açısından anlamlı fark yoktu. İlaveten AA kullanan ve MetS gelişen hastalarda ghrelin düzeyleri açısından anlamlı fark yoktu. DD kullanan ve Mets geliştirmiş olan hastalarda ghrelin düzeyleri açısından anlamlı fark yoktu. Serum ghrelin seviyeleri kontrol grubu ile kıyaslandığında bipolar hastalarda anlamlı oranda düşük bulunmuştur.
Sonuç: Çalışmamızda ikiuçlu bozukluk hastalarında genel populasyona oranla daha fazla oranda MetS görülmüştür. Serum ghrelin seviyeleri bipolar hastalar- da anlamlı düzeyde düşük bulundu. Bu sonucun kompansatuar bir mekanizma ile ilişkili olabileceği ya da hastalığı özgü farklı parametrelerin rol alabileceği düşünüldü.
Objective: The aim of this study is to investigate whether serum ghrelin levels are associated with metabolic syndrome (MetS) in bipolar patients. Methods: A total of 60 bipolar disorder patients and 30 healthy volunteers were included in the study. The patient group was separated into two subgroups according to the use of atypical antipsychotics (AA)-risperidone, quetiapine, olanzapine or mood stabilizers (MS)-lithium, valproic acid, carbamazepine, lamotrigine. The serum ghrelin level was measured by human ghrelin ELISA kits. Patients were diagnosed with MetS according to the National Cholesterol Education Program Adult Treatment Panel 3 (NCEP ATP 3) criteria; MetS was considered present when 3 or more criteria were met. Results: Among bipolar patients included in the study, 51.7% (n=31) were treated only with AA, while 48.8% (n=29) were treated with MS alone. MetS diagnosis was established in 36.7% (n=22) of patients. There was no significant difference in ghrelin levels when comparing patients with and without MetS. Additionally, there were no significant differences among the patients with MetS using AAs and among the patients with MetS using MSs in terms of ghrelin levels. The serum ghrelin levels were found to be significantly lower in bipolar patients compared to controls. Negative correlation was detected between ghrelin and fasting blood glucose. Conclusion: Our study found that, compared to the general population, MetS was more frequently observed in bipolar patients and that serum ghrelin level was significantly lower in those patients. This result might be associated either with a compensatory mechanism or with an involvement of other disease-specific parameters.
Objective: The aim of this study is to investigate whether serum ghrelin levels are associated with metabolic syndrome (MetS) in bipolar patients. Methods: A total of 60 bipolar disorder patients and 30 healthy volunteers were included in the study. The patient group was separated into two subgroups according to the use of atypical antipsychotics (AA)-risperidone, quetiapine, olanzapine or mood stabilizers (MS)-lithium, valproic acid, carbamazepine, lamotrigine. The serum ghrelin level was measured by human ghrelin ELISA kits. Patients were diagnosed with MetS according to the National Cholesterol Education Program Adult Treatment Panel 3 (NCEP ATP 3) criteria; MetS was considered present when 3 or more criteria were met. Results: Among bipolar patients included in the study, 51.7% (n=31) were treated only with AA, while 48.8% (n=29) were treated with MS alone. MetS diagnosis was established in 36.7% (n=22) of patients. There was no significant difference in ghrelin levels when comparing patients with and without MetS. Additionally, there were no significant differences among the patients with MetS using AAs and among the patients with MetS using MSs in terms of ghrelin levels. The serum ghrelin levels were found to be significantly lower in bipolar patients compared to controls. Negative correlation was detected between ghrelin and fasting blood glucose. Conclusion: Our study found that, compared to the general population, MetS was more frequently observed in bipolar patients and that serum ghrelin level was significantly lower in those patients. This result might be associated either with a compensatory mechanism or with an involvement of other disease-specific parameters.
Açıklama
Anahtar Kelimeler
Bipolar disorder, metabolic syndrome, ghrelin, ikiuçlu bozukluk, metabolik sendrom
Kaynak
Noropsikiyatri Arsivi-Archives of Neuropsychiatry
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
47
Sayı
4
Künye
Kalenderoğlu, A., Savaş, H. A., Gergerlioğlu, H. S., Başaralı, K., Yumru, M., Selek, S., Büyükbaş, S., Ergene, N., (2010). Correlation Between Metabolic Syndrome and Serum Ghrelin Levels in Bipolar Patients. Noropsikiyatri Arsivi-Archives of Neuropsychiatry, (47), 328-332. Doi: 10.4274/npa.y5648
